Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Multigene Assay Predicts Cancer Patient's Survival

By Labmedica International staff writers
Posted on 19 Aug 2014
Print article
Image: Histopathology of clear cell renal cell carcinoma (Photo courtesy of Nephron).
Image: Histopathology of clear cell renal cell carcinoma (Photo courtesy of Nephron).
Patients with clear cell renal cell carcinoma (ccRCC) have divergent survival outcomes and therapeutic responses, which may be determined by underlying molecular diversity.

A practical molecular assay has been developed that can identify subtypes with differential prognosis and response to targeted therapy and predict treatment and survival outcomes in kidney cancer patients.

Scientists at the Institute of Bioengineering and Nanotechnology (Republic of Singapore) and their colleagues conducted a retrospective study with a cohort of 279 ccRCC patients who underwent surgery at Singapore General Hospital (Republic of Singapore) between 1999 and 2012. They developed a practical expression-based assay with utility in formalin-fixed paraffin-embedded (FFPE) material that assigns biologic subtypes of ccRCC, characterized by differential prognosis and treatment response.

Ribonucleic acid (RNA) was extracted from a set of 55 FFPE samples (SGH-55) and processed for whole-genome expression analysis by Whole Genome (WG)-DASL (Illumina; San Diego, CA, USA). Quantitative polymerase chain reaction (qPCR) assays were designed for measuring expression in FFPE tissue; expression data for potential prognostic and normalization genes for SGH-55 were collected. A model assigning prognostic subtype was developed based on the combination of qPCR expression values of eight genes: chemokine (C-X-C motif) ligand 5 (CXCL5), ephrin A5 (EFNA5), endomucin (EMCN), laminin beta3 (LAMB3), plasminogen (PLG), preferentially expressed antigen in melanoma (PRAME), retinoic acid receptor responder (tazarotene induced) 1 (RARRES1), and solute carrier family 6 (neutral amino acid transporter), member 19 (SLC6A19).

Min-Han Tan, MBBS, PhD, the senior author of the study, said, “Our diagnostic assay successfully classified ccRCC into groups that correlated to different survival and treatment outcomes. This allows patients and doctors to make more educated choices in their treatment options. Outcomes can be very different. Some patients can be observed for years on end, some benefit from immediate treatment including surgery or targeted therapy, and for some patients, treatment can be futile. Experience is required in making the right judgment for patients. We hope our assay will play a role in helping that judgment.” The study was published on July 10, 2014, in the journal European Urology.

Related Links:

Institute of Bioengineering and Nanotechnology
Singapore General Hospital 
Illumina



Print article

Channels

Clinical Chemistry

view channel
Image: Dried blood spots are used to screen newborns for a number of rare inherited conditions. A new dried blood spot screening test has been developed for Niemann-Pick type C, a rare neurodegenerative condition that usually is not diagnosed until after damage to brain cells has begun (Photo courtesy of Washington University School of Medicine).

Newborn Screening Test Developed For Deadly Neurological Disorder

A newborn screening test has been introduced that identifies infants with Niemann-Pick disease type C, an often fatal condition in which cholesterol builds up and eventually destroys brain cells.... Read more

Pathology

view channel
Image: An IsoPSA test for prostate cancer detection and differentiation (Photo courtesy of Dr. Arnon Chait, PhD).

Novel Test Differentiates Malignant Prostate Cancer Grades

A promising new test has been introduced that detects prostate cancer more precisely than current tests, by identifying molecular changes in the prostate specific antigen (PSA) protein and can also differentiate... Read more

Industry News

view channel

R-Biopharm and Merck Partner on Companion Diagnostics

R-Biopharm AG (Darmstadt, Germany) and Merck KGaA (Darmstadt, Germany) have entered into an agreement that constitutes their first collaboration, which will initially focus on developing and launching companion diagnostics. Companion diagnostics play a central role in personalized medicine by helping to find specific... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.